Page last updated: 2024-11-08

serrawettin w2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

serrawettin W2: extracellular cyclic lipopeptide which promotes flagellum-dependent & -independent spreading growth of Serratia marcescens; amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164436
MeSH IDM0198718

Synonyms (6)

Synonym
serrawettin w2
140909-80-4
(3s,6r,12s,15r)-6-benzyl-3-[(2s)-butan-2-yl]-19-heptyl-9-[(1r)-1-hydroxyethyl]-12-(hydroxymethyl)-15-(2-methylpropyl)-1-oxa-4,7,10,13,16-pentazacyclononadecane-2,5,8,11,14,17-hexone
l-isoleucine, n-(n-(n-(n-(n-(3-hydroxy-1-oxodecyl)-d-leucyl)-l-seryl)-l-threonyl)-d-phenylalanyl)-, rho-lactone
DTXSID10930940
6-benzyl-3-(butan-2-yl)-19-heptyl-5,8,11,14,17-pentahydroxy-9-(1-hydroxyethyl)-12-(hydroxymethyl)-15-(2-methylpropyl)-1-oxa-4,7,10,13,16-pentaazacyclononadeca-4,7,10,13,16-pentaen-2-one

Research Excerpts

Overview

Serrawettin W2 was shown to be a novel cyclodepsipeptide containing a fatty acid (3-hydroxydecanoic acid) and five amino acids.

ExcerptReferenceRelevance
"Serrawettin W2 was shown to be a novel cyclodepsipeptide containing a fatty acid (3-hydroxydecanoic acid) and five amino acids."( A novel extracellular cyclic lipopeptide which promotes flagellum-dependent and -independent spreading growth of Serratia marcescens.
Hara-Hotta, H; Isa, K; Kaneda, K; Matsuyama, T; Nakagawa, Y; Yano, I, 1992
)
1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (30.00)18.2507
2000's2 (20.00)29.6817
2010's4 (40.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]